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days and $15,707 (both p < .001); corresponding ﬁgures
for those with minor bleeding (n = 296) were 4.5 days
and $11,243 (both p < .001). ORs for mortality were 2.0
for major bleeding (p = .024) and 1.2 for minor bleeding
(p = .613). 
CONCLUSION: Ischemic complications and bleeding in
patients undergoing PCI are costly and associated with
poor outcome. These events occur frequently in clinical
practice.
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OBJECTIVES: Recent studies (e.g. NHANES II and
DECODE) indicate that increased post-prandial blood
glucose level (PPG) is an independent risk factor for 
coronary heart disease (CHD), stroke, and cardiovascu-
lar disease (CVD) death. A modeling study was per-
formed to combine best available data with costs of CVD
complications to project possible long-term clinical and
cost outcomes for non-diabetic people with different
baseline PPGs. 
METHODS: Risks of CHD, stroke, and CVD death
derived from Framingham formulae were combined with
published 2-hour PPG-dependent hazard ratios for 
incident CHD, stroke, and CVD death to calculate CVD
events and subsequent changes in life expectancy (LE)
dependent on different baseline PPG levels for a typical
non-diabetic population. Direct costs of CVD complica-
tions were projected over 50 years using a Markov model.
A US Medicare payer perspective was taken. Only direct
costs were included. Discounted rates of 3% p.a. were
used. Sensitivity analysis was performed to identify 
parameters with the greatest impact on outcomes. 
RESULTS: A typical population of non-diabetic patients
with baseline age of 60 years and 2-hour PPG levels of
14.6, 12.6, 10.6, or 8.6mmol/l were calculated to have
LE of 19.93, 21.23, 22.25, and 23.02 years respectively.
Lifetime costs per patient due to CVD complications were
calculated to be $20,186, $19,417, $18,366, $17,151
respectively. Parameters with the greatest impact on 
outcomes were baseline age of the population, PPG 
levels, and other CVD risk factors including blood 
pressure and lipids. 
CONCLUSIONS: Lower 2-hPPG levels are associated
with higher life expectancy and reduced costs due to 
cardiovascular complications. Considering the important
impact of PPG and other modiﬁable CVD risk factors, a
multifactorial approach to addressing these risk factors 
is recommended. Interventions aimed at improving PPG
levels could be cost-effective, due to the additional costs
of interventions being offset by reduced costs of CVD
complications.
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Heart failure (HF) affects nearly 5 million Americans with
a 5-year mortality rate of 50%. There is limited infor-
mation on the relationship between patient-reported out-
comes (e.g., utilities, quality of life) and New York Heart
Association (NYHA) classiﬁcation. 
OBJECTIVE: The objective of this study was to compare
the correlation between utilities, QOL scores and NYHA
class. 
METHODS: One hundred-two ambulatory HF patients
provided utilities using the Rating Scale (RS), Time-
Trade-Off (TTO) and Standard Gamble (SG) methods
and QOL using the Medical Outcomes Study Short-Form
36 (SF-36) and the Minnesota Living with Heart Failure
Questionnaire (MLHFQ). NYHA class was extracted
from patient charts. Data were analyzed using Pearson’s
Correlation Coefﬁcients and ANCOVA. 
RESULTS: There were 11 Class I, 40 Class II, 34 Class
III, and 17 Class IV HF patients. Mean age varied by 
class (47.5, 55.3, 51.8, and 55.0 years, respectively).
More patients were female (62.0% overall), except Class
I (36.4% female). Mean physical component summary
scores (PCS) from the SF-36 were signiﬁcantly different
but mental component summary scores did not vary by
NYHA class. Mean total MLHFQ scores were 20.2, 46.4,
61.9, and 80.8, respectively. Mean utility scores from the
RS were 0.68, 0.60, 0.47, and 0.40; from the SG were
0.90, 0.85, 0.71, and 0.67; and from the TTO were 0.87,
0.88, 0.68, and 0.62, respectively. All means were
adjusted for age and gender. The PCS, MLHFQ, and
utility measures showed a consistent monotonic relation-
ship with increasing HF class. Correlation between utility
measures and the PCS and MLHFQ were highly signiﬁ-
cant (PCS r = 0.30 to 0.47; and MLHFQ r = -0.53 to 
-0.33 for the RS, SG, and TTO; p < 0.001). 
CONCLUSIONS: Results support prior belief that
patient-reported outcomes worsen with HF progression.
QOL and utility measures may assist clinicians quantify-
ing the impact of HF on patients’ well-being.
